{
    "clinical_study": {
        "@rank": "161506", 
        "acronym": "ERADICATE Hp", 
        "arm_group": [
            {
                "arm_group_label": "RHB-105", 
                "arm_group_type": "Experimental", 
                "description": "RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Capsules that look like the RHB-105 product but contain no active ingredient."
            }
        ], 
        "brief_summary": {
            "textblock": "The \"test and treat\" strategy for treating dyspeptic patients who are H. pylori positive is\n      rapidly becoming the standard of care.  This study will test the effectiveness of RHB-105, a\n      new triple therapy to treat H. pylori infection in dyspeptic patients."
        }, 
        "brief_title": "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105", 
        "condition": [
            "Dyspepsia", 
            "Helicobacter Pylori Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Helicobacter Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a, randomized, double-blind, placebo-controlled study of RHB-105 in adult subjects\n      complaining of epigastric discomfort that have been screened and found to be positive for H.\n      pylori infection via 13C Urea Breath Test (UBT) and fecal antigen test.\n\n      Eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the\n      active arm (RHB-105) (n=60).  Subjects will receive study drug for 14 consecutive days.\n      Eradication of H. pylori infection will be determined based on 13C UBT conducted between 28\n      to 56 days after completion of study drug therapy.\n\n      Subjects will be unblinded upon 13C UBT analysis.  This will provide timely active therapy\n      to all subjects enrolled in this study. Subjects in the placebo arm will be entitled to\n      receive standard-of-care as prescribed by the treating physician following un-blinding.\n\n      Eradication failures (13C UBT-positive) in the active study drug arm will undergo upper\n      endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin,\n      clarithromycin, and metronidazole). Culture and sensitivity directed therapy as prescribed\n      by the treating physician will be offered to these subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Be \u226518 years of age and \u2264 65 years\n\n          2. Have symptoms consistent with dyspepsia of at least two weeks duration (defined as\n             recurrent pain or discomfort centered in the upper abdomen, often with a relation to\n             meals)\n\n          3. Be positive for H. pylori by 13C Urea Breath Test (UBT) and also by fecal antigen\n             test\n\n          4. Be informed of the nature of the study and provide written informed consent before\n             any study specific procedures are performed (or have a legally authorized\n             representative sign consent)\n\n        Exclusion Criteria:\n\n          1. Have alarm symptoms/signs (including unexplained anemia [iron deficiency), melena /\n             hematemesis, anorexia, dysphagia, jaundice, weight loss)\n\n          2. Have taken antibiotics in the 4 weeks prior to screening\n\n          3. Have taken bismuth containing medications such as peptobismol in the 4 weeks prior to\n             screening\n\n          4. Have a history of any previous esophageal or gastric surgery, except for simple\n             closure of perforated ulcer\n\n          5. Have a history of gastric outlet obstruction\n\n          6. Have a history of hypersecretory state such as Zollinger-Ellison Syndrome\n\n          7. Have a history of gastric cancer\n\n          8. Have the presence of active gastric and duodenal ulcers or presence of 3 or more\n             active ulcers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980095", 
            "org_study_id": "RHB-105-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "RHB-105", 
                "description": "The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:\nRifabutin 150 mg\nAmoxicillin 3000 mg\nOmeprazole 120 mg\nSubjects will take study drug every 8 hours with food for 14 consecutive days.", 
                "intervention_name": "RHB-105", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects will take 4 placebo capsules every 8 hours with food for 14 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Helicobacter pylori", 
            "H. pylori", 
            "Dyspepsia"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rquiceno@act-trials.com", 
                    "last_name": "Rosa Quiceno", 
                    "phone": "714-774-7777", 
                    "phone_ext": "240"
                }, 
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials, LLC"
                }, 
                "investigator": {
                    "last_name": "Michael DeMicco, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jcalleros@catalinari.com", 
                    "last_name": "Joe Calleros", 
                    "phone": "909-203-4707"
                }, 
                "facility": {
                    "address": {
                        "city": "Chino", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91710"
                    }, 
                    "name": "Catalina Research Institute"
                }, 
                "investigator": {
                    "last_name": "Gilbert Martinez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Cgoodwinjra@aol.com", 
                    "last_name": "Cathy Goodwin, CCRC", 
                    "phone": "561-743-4160"
                }, 
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33458"
                    }, 
                    "name": "Jupiter Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Michael Schwartz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fmoney@serrg.com", 
                    "last_name": "Felicia Money", 
                    "phone": "706-596-4894"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31904"
                    }, 
                    "name": "Columbus Regional Research Institute"
                }, 
                "investigator": {
                    "last_name": "Michael Steinbook, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "timslocum@medpharmics.com", 
                    "last_name": "Tim Slocum", 
                    "phone": "504-265-9951"
                }, 
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }, 
                    "name": "MedPharmics"
                }, 
                "investigator": {
                    "last_name": "Robert Jeanfreau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wendym@petersmedicalresearch.com", 
                    "last_name": "Wendy Meris", 
                    "phone": "336-883-9773"
                }, 
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Peters Medical Research"
                }, 
                "investigator": {
                    "last_name": "Lenin Peters, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "imajeed@wakeresearch.com", 
                    "last_name": "Irfan Majeed", 
                    "phone": "919-781-2514"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Wake Research Associates"
                }, 
                "investigator": {
                    "last_name": "Charles Barish, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients", 
        "other_outcome": [
            {
                "description": "Patient reported outcome - Severity of Dyspepsia Assessment (SODA) score prior to and after treatment with study drug", 
                "measure": "Severity of Dyspepsia Assessment (SODA)", 
                "safety_issue": "No", 
                "time_frame": "43-71 days"
            }, 
            {
                "description": "Pharmacogenetic - cytochrome P450 (CYP) 2C19 status", 
                "measure": "Pharmacogenetic", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }
        ], 
        "overall_contact": {
            "email": "kjones@clinipace.com", 
            "last_name": "Kirsten Jones, BSCR, CCRA", 
            "phone": "919-797-9482"
        }, 
        "overall_contact_backup": {
            "email": "kwatson@clinipace.com", 
            "last_name": "Kevin Watson, M.S.", 
            "phone": "949-224-2816"
        }, 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "David Y Graham, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The occurrence of H. pylori eradication as confirmed via 13C UBT testing", 
            "safety_issue": "No", 
            "time_frame": "28-56 days after completion of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety - The occurrence and severity of adverse events during the study and changes from baseline in hematology and chemistry laboratory values.", 
                "safety_issue": "Yes", 
                "time_frame": "42 days"
            }, 
            {
                "measure": "Change from Baseline in the trough concentration of amoxicillin, omeprazole, rifabutin and rifabutin metabolite 25-O-desacetyl-rifabutin on Day 8", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Change from Baseline in the trough concentration of amoxicillin, omeprazole, rifabutin and rifabutin metabolite 25-O-desacetyl-rifabutin on Day 15", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }
        ], 
        "source": "RedHill Biopharma Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RedHill Biopharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}